Alemtuzumab

Active ingredient description

Alemtuzumab is a genetically engineered humanised IgG1 kappa monoclonal antibody specific for a 21-28 kD lymphocyte cell surface glycoprotein (CD52) expressed primarily on the surface of normal and malignant peripheral blood B and T cell lymphocytes. Alemtuzumab acts through antibody-dependent cellular cytolysis and complement-mediated lysis following cell surface binding to CD52, a cell surface antigen present at high levels on T (CD3+) and B (CD19+) lymphocytes, and at lower levels on natural killer cells, monocytes, and macrophages.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Alemtuzumab
L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AA Selective immunosuppressants
Discover more medicines within L04AA34

Medicines

Alemtuzumab is the active ingredient of these drugs:

Drug
Countries

United States

Australia Austria Brazil Canada Cyprus

Canada

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of product characteristics (SPC)

3D molecular structure

3D representation of the active ingredient's molecular structure

Unique ingredient identifier (UNII)

3A189DH42V - ALEMTUZUMAB

CAS registry number

216503-57-0 - alemtuzumab

SNOMED-CT

129472003 - Alemtuzumab (substance)